Chris Viehbacher to leave GlaxoSmithKline

Share this article:

Chris Viehbacher, GlaxoSmithKline's executive director and president, North American pharmaceuticals, has announced plans to leave the company.

Viehbacher resigned his position on GSK's board on Sept 8, and will leave the company entirely on December 1, 2008, according to a statement. Andrew Witty, currently CEO at GSK, was appointed to that position upon the retirement of CEO Jean-Pierre Garnier last May. Viehbacher had been a contender for the CEO role. 

Witty said of Viehbacher in the statement, “I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavors.”

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.